MA39838B1 - Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 - Google Patents

Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4

Info

Publication number: MA39838B1
Authority: MA; Morocco
Prior art keywords: bicyclic heteroaryl; fused aryl; aryl compounds; irak4 inhibitors; irak4
Prior art date: 2014-04-04

Application number

MA39838A

Other languages

English (en)

Other versions

MA39838A (fr

Inventor

Akshay Patny

Seungil Han

Eddine Saiah

Christoph Wolfgang Zapf

Joseph Walter Strohbach

John David Trzupek

Xiaolun Wang

David Hepworth

David Randolph Anderson

Mark Edward Bunnage

Kevin Joseph Curran

Christoph Martin Dehnhardt

Lori Krim Gavrin

Joel Adam Goldberg

Horng-Chih Huang

Arthur Lee

Katherine Lin Lee

Frank Eldridge Lovering

Michael Dennis Lowe

John Paul Mathias

Nikolaos Papaioannou

Betsy Susan Pierce

Richard Vargas

Stephen Wayne Wright

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-04

Filing date

2015-03-26

Publication date

2019-05-31

2015-03-26 Application filed by Pfizer filed Critical Pfizer

2017-02-08 Publication of MA39838A publication Critical patent/MA39838A/fr

2019-05-31 Publication of MA39838B1 publication Critical patent/MA39838B1/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pyrrole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

MA39838A 2014-04-04 2015-03-26 Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 MA39838B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461975473P	2014-04-04	2014-04-04
EP15717250.3A EP3126330B1 (fr)	2014-04-04	2015-03-26	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
PCT/IB2015/052251 WO2015150995A1 (fr)	2014-04-04	2015-03-26	Composés à base d'hétéroaryle ou d'aryle fusionné-bicyclique et leur utilisation comme composés inhibiteurs de l'irak 4

Publications (2)

Publication Number	Publication Date
MA39838A MA39838A (fr)	2017-02-08
MA39838B1 true MA39838B1 (fr)	2019-05-31

Family

ID=52988358

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA39838A MA39838B1 (fr)	2014-04-04	2015-03-26	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
MA52856A MA52856B1 (fr)	2014-04-04	2015-03-26	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA52856A MA52856B1 (fr)	2014-04-04	2015-03-26	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4

Country Status (46)

Country	Link
US (6)	US9458168B2 (fr)
EP (2)	EP3126330B1 (fr)
JP (2)	JP6177456B2 (fr)
KR (1)	KR101901044B1 (fr)
CN (1)	CN106458912B (fr)
AP (1)	AP2016009514A0 (fr)
AR (1)	AR099955A1 (fr)
AU (1)	AU2015242291B2 (fr)
BR (1)	BR112016023117B1 (fr)
CA (1)	CA2944475C (fr)
CL (1)	CL2016002524A1 (fr)
CR (1)	CR20160456A (fr)
CU (1)	CU24406B1 (fr)
CY (2)	CY1121694T1 (fr)
DK (2)	DK3126330T3 (fr)
DO (1)	DOP2016000271A (fr)
EA (1)	EA032559B1 (fr)
EC (1)	ECSP16076566A (fr)
ES (2)	ES2910128T3 (fr)
GE (2)	GEAP201814288A (fr)
GT (1)	GT201600215A (fr)
HR (2)	HRP20190506T1 (fr)
HU (2)	HUE057876T2 (fr)
IL (1)	IL248158B (fr)
LT (2)	LT3536685T (fr)
MA (2)	MA39838B1 (fr)
MD (1)	MD4779B1 (fr)
ME (1)	ME03599B (fr)
MX (1)	MX374729B (fr)
MY (1)	MY192521A (fr)
NI (1)	NI201600152A (fr)
NZ (1)	NZ724578A (fr)
PE (1)	PE20161251A1 (fr)
PH (1)	PH12016501972A1 (fr)
PL (2)	PL3536685T3 (fr)
PT (2)	PT3536685T (fr)
RS (2)	RS58597B1 (fr)
SG (1)	SG11201608110WA (fr)
SI (2)	SI3536685T1 (fr)
SV (1)	SV2016005295A (fr)
TR (1)	TR201904658T4 (fr)
TW (3)	TWI580678B (fr)
UA (1)	UA121467C2 (fr)
UY (1)	UY36056A (fr)
WO (1)	WO2015150995A1 (fr)
ZA (1)	ZA201606550B (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL3321359T3 (pl)	2005-04-11	2021-06-28	Horizon Pharma Rheumatology Llc	Wariantowe postacie oksydazy moczanowej i ich zastosowanie
PL398781A1 (pl)	2009-06-25	2012-11-19	Savient Pharmaceuticals, Inc.	Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy
MX366318B (es)	2010-11-19	2019-07-05	Ligand Pharm Inc	Derivados de aminas heterocíclicas que inhiben la transducción de señal mediana por cinasa asociada con el receptor de interleucina-1.
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
RS58597B1 (sr)	2014-04-04	2019-05-31	Pfizer	Biciklično-spojena heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora
EP3126354B1 (fr)	2014-04-04	2020-01-22	H. Lundbeck A/S	Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
US20180228907A1 (en)	2014-04-14	2018-08-16	Arvinas, Inc.	Cereblon ligands and bifunctional compounds comprising the same
JP2018527337A (ja)	2015-08-13	2018-09-20	ファイザー・インク	二環式縮合ヘテロアリールまたはアリール化合物
ES2865199T3 (es)	2015-08-27	2021-10-15	Pfizer	Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
WO2018026877A1 (fr)	2016-08-05	2018-02-08	Calitor Sciences, Llc	Méthode de préparation de composés de quinoléine-4-ol substitués
US11542261B2 (en)	2016-08-17	2023-01-03	Children's Hospital Medical Center	Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
US11254667B2 (en)	2016-08-17	2022-02-22	Children's Hospital Medical Center	Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
CN116983302A (zh) *	2016-10-13	2023-11-03	特拉维尔治疗公司	用于治疗肾脏疾病或病症的联苯磺酰胺化合物
EP3538135A4 (fr)	2016-11-11	2020-07-29	Horizon Pharma Rheumatology LLC	Polythérapies de molécules de prednisone et d'uricase et leurs utilisations
US20200237881A1 (en)	2019-01-30	2020-07-30	Horizon Pharma Rheumatology Llc	Reducing immunogenicity to pegloticase
KR20180066296A (ko) *	2016-12-07	2018-06-19	서울대학교산학협력단	토파시티닙을 포함하는 고염증 증상의 예방 또는 치료용 약학적 조성물 및 토파시티닙을 포함하는 고염증 증상의 예방 또는 개선용 건강기능식품 조성물
EP3824906A1 (fr)	2016-12-21	2021-05-26	Amgen Inc.	Formulations d'anticorps anti-tnf alpha
JOP20180011A1 (ar)	2017-02-16	2019-01-30	Gilead Sciences Inc	مشتقات بيرولو [1، 2-b]بيريدازين
PT3621960T (pt)	2017-05-11	2021-09-16	Bristol Myers Squibb Co	Tienopiridinas e benzotiofenos úteis como inibidores de irak4
CN108558854A (zh) *	2017-06-10	2018-09-21	曹艳	一种治疗革兰氏阳性菌引起的感染的药物及其合成方法
GB201712282D0 (en)	2017-07-31	2017-09-13	Nodthera Ltd	Selective inhibitors of NLRP3 inflammasome
US11358948B2 (en)	2017-09-22	2022-06-14	Kymera Therapeutics, Inc.	CRBN ligands and uses thereof
IL273432B (en)	2017-09-22	2022-09-01	Kymera Therapeutics Inc	Protein compounds and their uses
KR20250037575A (ko)	2017-10-20	2025-03-17	반더빌트유니버시티	무스카린성 아세틸콜린 수용체 m4의 길항제
WO2019089422A1 (fr)	2017-10-30	2019-05-09	Synblia Therapeutics, Inc.	Inhibiteurs d'irak4 et leurs utilisations
CA3081324A1 (fr)	2017-10-31	2019-05-09	Vanderbilt University	Antagonistes du recepteur muscarinique m4 a l'acetylcholine
EP3710443A1 (fr)	2017-11-17	2020-09-23	Arvinas Operations, Inc.	Composés et procédés pour la dégradation ciblée de polypeptides de kinase 4 associés au récepteur de l'interleukine 1
WO2019111218A1 (fr)	2017-12-08	2019-06-13	Cadila Healthcare Limited	Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs d'irak4
IL315310A (en)	2017-12-26	2024-10-01	Kymera Therapeutics Inc	Irak degraders and uses thereof
WO2019140380A1 (fr)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Agents de dégradation de protéines et utilisations associées
EP3737675A4 (fr)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	Ligands crbn et leurs utilisations
AU2019215598B2 (en)	2018-01-31	2023-12-21	Merck Patent Gmbh	Quinoline compounds as IRAK inhibitors and uses thereof
IL276411B2 (en)	2018-02-02	2024-04-01	Univ Vanderbilt	M4 muscarinic acetylcholine receptor antagonists
CR20200347A (es)	2018-02-13	2020-09-23	Gilead Sciences Inc	Inhibidores pd-1/pd-l1
CA3090275A1 (fr) *	2018-02-14	2019-08-22	Dana-Farber Cancer Institute, Inc.	Composes degradant les irak et utilisations de ces derniers
CN108299397B (zh) *	2018-03-21	2019-01-29	佳木斯大学附属第一医院	一种用于降血压的活性药物及其制备方法
KR102591947B1 (ko)	2018-04-19	2023-10-25	길리애드 사이언시즈, 인코포레이티드	Pd-1/pd-l1 억제제
EP3810144A4 (fr) *	2018-06-04	2022-08-17	Chemistryrx	Compositions topiques pour stimuler la pousse des cheveux
WO2020010177A1 (fr)	2018-07-06	2020-01-09	Kymera Therapeutics, Inc.	Ligands crbn tricycliques et leurs utilisations
EP3817822A4 (fr)	2018-07-06	2022-07-27	Kymera Therapeutics, Inc.	Agents de dégradation de protéines et leurs utilisations
TWI898556B (zh)	2018-07-13	2025-09-21	美商基利科學股份有限公司	吡咯并[1,2-b]嗒衍生物
CN109147870A (zh) *	2018-07-26	2019-01-04	刘滨	基于条件随机场的固有无序蛋白质的识别方法
KR102660255B1 (ko)	2018-08-13	2024-04-25	길리애드 사이언시즈, 인코포레이티드	Irak4 억제제로서의 피롤로[1,2-b]피리다진 유도체
TWI727392B (zh)	2018-08-13	2021-05-11	美商基利科學股份有限公司	噻二唑irak4抑制劑
CN112533924B (zh)	2018-08-13	2023-11-28	吉利德科学公司	作为IRAK4抑制剂的吡咯并[1,2-b]哒嗪衍生物
CA3119773A1 (fr)	2018-11-30	2020-06-04	Kymera Therapeutics, Inc.	Agents de degradation de kinases de type irak et leurs utilisations
DE102018221954A1 (de) *	2018-12-17	2020-06-18	Robert Bosch Gmbh	Recheneinrichtung und Verfahren zum Betreiben einer Recheneinrichtung
WO2020160322A1 (fr) *	2019-01-30	2020-08-06	Horizon Pharma Rheumatology Llc	Tolérisation réduisant l'intolérance à la pegloticase et prolongeant l'effet d'abaissement de l'urate (triple)
CN111662295B (zh) *	2019-03-05	2021-09-10	珠海宇繁生物科技有限责任公司	一种irak4激酶抑制剂及其制备方法
KR102289661B1 (ko) *	2019-05-15	2021-08-17	가톨릭대학교 산학협력단	요산분해효소를 과발현하는 줄기세포를 유효성분으로 포함하는 통풍의 예방 또는 치료용 조성물
ES2960521T3 (es)	2019-07-18	2024-03-05	Bristol Myers Squibb Co	Compuestos de pirazolo[3,4-D]pirrolo[1,2-B]piridazinilo útiles como inhibidores de IRAK4
WO2021011724A1 (fr)	2019-07-18	2021-01-21	Bristol-Myers Squibb Company	Composés hétéroaryle tricycliques utiles en tant qu'inhibiteurs d'irak4
ES3036306T3 (en)	2019-07-23	2025-09-17	Bristol Myers Squibb Co	Thienopyridinyl and thiazolopyridinyl compounds useful as irak4 inhibitors
WO2021019373A1 (fr)	2019-07-31	2021-02-04	Sea4Us - Biotecnologia E Recursos Marinhos, Lda.	Composés analogues de niténine et leur utilisation dans le traitement de la douleur chronique et aiguë
KR20220044211A (ko) *	2019-08-06	2022-04-06	브리스톨-마이어스 스큅 컴퍼니	Irak4 억제제로서 유용한 비시클릭 헤테로시클릭 화합물
CN112679472A (zh) *	2019-10-17	2021-04-20	北京桦冠医药科技有限公司	具有irak4抑制剂活性的异喹啉类化合物
EP4057989A1 (fr)	2019-11-14	2022-09-21	Pfizer Inc.	Combinaisons de 1-(((2s,3s,4s)-3-éthyl-4-fluoro-5-oxopyrrolidin-2-yl)méthoxy)-7-méthoxyisoquinoléine-6-carboxamide et formes pharmaceutiques orales
US20210154292A1 (en) *	2019-11-21	2021-05-27	Chemocentryx, Inc.	Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies
JP2023509366A (ja)	2019-12-17	2023-03-08	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
EP4076524A4 (fr)	2019-12-17	2023-11-29	Kymera Therapeutics, Inc.	Agents de dégradation d'irak et leurs utilisations
EP4096666A4 (fr) *	2020-01-29	2024-05-22	Georgetown University	Compositions et méthodes de traitement de troubles neurodégénératifs, neurodéveloppementaux, myodégénératifs et du stockage lysosomal
WO2021158495A1 (fr)	2020-02-03	2021-08-12	Bristol-Myers Squibb Company	Composés de benzo[5,6] [1,4]dioxino[2,3-b]pyridine utiles en tant qu'inhibiteurs de l'irak4
US11618751B1 (en)	2022-03-25	2023-04-04	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
EP4125900A1 (fr)	2020-04-04	2023-02-08	Pfizer Inc.	Procédés de traitement de la maladie à coronavirus 2019
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
KR102871840B1 (ko)	2020-09-30	2025-10-15	아사히 가세이 파마 가부시키가이샤	거대고리 화합물
AU2020471055B8 (en)	2020-09-30	2023-12-21	Asahi Kasei Pharma Corporation	Pyrimidine- and nitrogen-containing bicyclic compound
US11866405B2 (en)	2020-12-10	2024-01-09	Astrazeneca Ab	Substituted indazoles as IRAK4 inhibitors
TW202241891A (zh)	2020-12-30	2022-11-01	美商凱麥拉醫療公司	Irak降解劑及其用途
MX2023009178A (es)	2021-02-15	2023-08-21	Kymera Therapeutics Inc	Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
US12171768B2 (en)	2021-02-15	2024-12-24	Kymera Therapeutics, Inc.	IRAK4 degraders and uses thereof
US11319319B1 (en)	2021-04-07	2022-05-03	Ventus Therapeutics U.S., Inc.	Compounds for inhibiting NLRP3 and uses thereof
IL308314A (en)	2021-05-07	2024-01-01	Kymera Therapeutics Inc	CDK2 compounds and their uses
AR127505A1 (es) *	2021-10-29	2024-01-31	Kymera Therapeutics Inc	Degradadores irak-4 y síntesis de los mismos
WO2023147594A2 (fr)	2022-01-31	2023-08-03	Kymera Therapeutics, Inc.	Agents de dégradation d'irak et leurs utilisations
MX2024009843A (es)	2022-02-14	2024-08-22	Astrazeneca Ab	Inhibidores de irak4.
WO2023192479A1 (fr)	2022-03-31	2023-10-05	Rigel Pharmaceuticals, Inc.	Inhibiteurs d'irak tricycliques
EP4532499A1 (fr)	2022-05-26	2025-04-09	Astrazeneca AB	Formes solides d'hétérocyclylamides utilisées comme inhibiteurs de l'irak 4
WO2023235433A1 (fr) *	2022-06-01	2023-12-07	Rigel Pharmaceuticals, Inc.	Inhibiteurs bicycliques d'irak
US12331048B2 (en)	2022-10-31	2025-06-17	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
EP4613748A1 (fr)	2022-11-04	2025-09-10	Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.	Agent de dégradation d'irak 4 et son utilisation
WO2024194756A1 (fr)	2023-03-17	2024-09-26	Pfizer Inc.	Modulation de l'immunité innée de l'arn
US12269875B2 (en)	2023-08-03	2025-04-08	Jeff R. Peterson	Gout flare prevention methods using IL-1BETA blockers
WO2025036841A1 (fr)	2023-08-11	2025-02-20	Astrazeneca Ab	Inhibiteurs d'irak4 cristallins
CN118978508B (zh) *	2024-08-02	2025-09-16	上海信诺维生物医药有限公司	一种含氮杂环化合物
CN120842197A (zh) *	2025-09-24	2025-10-28	上海市刑事科学技术研究院	一种羟基可替宁-d3的制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3673238A (en) *	1970-02-10	1972-06-27	Usv Pharma Corp	2-naphthoic acid derivatives
JPS528238B2 (fr)	1973-10-11	1977-03-08
EP0028489B1 (fr)	1979-11-05	1983-10-05	Beecham Group Plc	Dérivés d'enzymes et leur préparation
DE3882894T2 (de)	1987-10-20	1994-03-17	Mitsui Toatsu Chemicals	1,2-Naphtalocyanine, Infrarotabsorber und sie verwendende Aufzeichnungsmaterialien.
US4861795A (en) *	1988-06-23	1989-08-29	Rorer Pharmaceutical Corporation	Treatment of conditions requiring enhanced oxygen availability to mammalian tissues
JP2671059B2 (ja) *	1990-11-30	1997-10-29	富士レビオ株式会社	ナフトエ酸誘導体
JPH05148222A (ja)	1991-11-29	1993-06-15	Fujirebio Inc	ナフトエ酸誘導体
US5837689A (en) *	1993-06-16	1998-11-17	Glycomed Incorporated	Sialyl lewis-x mimetics containing naphthyl backbones
AU686691B2 (en)	1994-01-12	1998-02-12	F. Hoffmann-La Roche Ag	Novel azepanes and homologs thereof
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
TR199600329A2 (tr)	1995-05-05	1997-03-21	Hoffmann La Roche	Seker alkollerin yeni sülfürik asit esterleri.
GB9514265D0 (en) *	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
CN1149196C (zh)	1998-07-06	2004-05-12	布里斯托尔-迈尔斯斯奎布公司	作为血管紧张肽和内皮肽受体双重拮抗剂的联苯基磺酰胺
AU6578900A (en) *	1999-07-07	2001-01-30	Astrazeneca Uk Limited	Quinazoline derivatives
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
DE60134679D1 (de) *	2000-10-20	2008-08-14	Eisai R&D Man Co Ltd	Stickstoff enthaltende aromatische Heterozyklen
PL372887A1 (en)	2002-02-27	2005-08-08	Pfizer Products Inc.	Acc inhibitors
EP1724268A4 (fr) *	2004-02-20	2010-04-21	Kirin Pharma Kk	Compose ayant une activite d'inhibition du tgf-beta et composition pharmaceutique contenant celui-ci
CA2566108C (fr)	2004-05-12	2010-04-06	Pfizer Products Inc.	Derives de proline et leur utilisation en tant qu'inhibiteurs de la dipeptidyl-peptidase iv
CA2612260C (fr)	2005-07-07	2013-10-29	Abbott Laboratories	Promoteurs d'apoptose
US7572809B2 (en)	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
NL2000581C2 (nl)	2006-04-20	2008-01-03	Pfizer Prod Inc	Aangecondenseerde fenylamidoheterocyclische verbindingen.
CA2670422C (fr)	2006-11-29	2011-09-06	Pfizer Products Inc.	Inhibiteurs de la spirocetoneacetyl-coa carboxylase
KR101763674B1 (ko)	2007-01-22	2017-08-01	지티엑스, 인코포레이티드	핵 수용체에 결합하는 물질
US9623021B2 (en)	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
WO2008103354A2 (fr)	2007-02-20	2008-08-28	Cropsolution, Inc.	Modulateurs de l'acétyl-coenzyme a carboxylase et procédés d'utilisation de ceux-ci
US20090023773A1 (en)	2007-06-27	2009-01-22	Painceptor Pharma Corporation	Compositions and methods for modulating gated ion channels
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
CN101245022A (zh) *	2008-03-21	2008-08-20	东华大学	3,5-双(2,4-二氨基苯氧基)-2-萘甲酸的制备方法
CA2724603A1 (fr)	2008-05-28	2009-12-03	Pfizer Inc.	Inhibiteurs de la pyrazolospirocetone acetyl-coa carboxylase
CA2724774C (fr)	2008-05-28	2013-06-25	Pfizer Inc.	Inhibiteurs de la pyrazolospirocetone acetl-coa carboxylase
DE102008027574A1 (de)	2008-06-10	2009-12-17	Merck Patent Gmbh	Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
CN101353307A (zh) *	2008-07-25	2009-01-28	东华大学	3,5-双(2,6-二硝基-4-三氟甲基苯氧基)-2-萘甲酸的制备方法
CA2729581A1 (fr)	2008-07-29	2010-02-04	Pfizer Inc.	Heteroaryles fluores
EP2334687B9 (fr)	2008-08-28	2012-08-08	Pfizer Inc.	Dérivés de dioxa-bicyclo[3.2.1.]octane-2,3,4-triol
TW201038580A (en)	2009-02-02	2010-11-01	Pfizer	4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
EP2406230A1 (fr)	2009-03-11	2012-01-18	Pfizer Inc.	Indazole amides substitués
UA99882C2 (uk)	2009-03-11	2012-10-10	Пфайзер Інк.	Похідні бензофуранілу, фармацевтична композиція та спосіб лікування захворювань (варіанти)
JP2012520868A (ja)	2009-03-20	2012-09-10	ファイザー・インク	３−オキサ−７−アザビシクロ［３．３．１］ノナン
CA2759843A1 (fr)	2009-05-08	2010-11-10	Pfizer Inc.	Modulateurs de gpr119
CA2759891A1 (fr)	2009-05-08	2010-11-11	Pfizer Inc.	Modulateurs du gpr119
JP2012528847A (ja)	2009-06-05	2012-11-15	ファイザー・インク	Ｇｐｒ１１９調節因子としてのｌ−（ピペリジン−４−イル）−ピラゾール誘導体
WO2011005611A1 (fr)	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Agonistes du récepteur de la neuromédine u et leurs utilisations
WO2011153553A2 (fr)	2010-06-04	2011-12-08	The Regents Of The University Of California	Méthodes et compositions pour l'inhibition de kinases
WO2011159781A2 (fr)	2010-06-17	2011-12-22	Senomyx, Inc.	Modulateurs de goût amer
JP5860960B2 (ja)	2011-07-26	2016-02-16	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	置換キノリン類及び医薬としてのそれらの使用
WO2013142390A1 (fr)	2012-03-21	2013-09-26	Gtx, Inc.	Inhibiteurs de la sous-famille 1c3 d'aldo-céto réductase (akr1c3)
WO2014039820A1 (fr)	2012-09-07	2014-03-13	Gtx, Inc.	Inhibiteurs de la sous-famille 1c3 de l'aldo-céto réductase (akr1c3)
SG11201600373YA (en)	2013-07-31	2016-02-26	Gilead Sciences Inc	Syk inhibitors
RS58597B1 (sr) *	2014-04-04	2019-05-31	Pfizer	Biciklično-spojena heteroaril ili aril jedinjenja i njihova upotreba kao irak4 inhibitora
ES2865199T3 (es) *	2015-08-27	2021-10-15	Pfizer	Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4

2015
- 2015-03-26 RS RS20190450A patent/RS58597B1/sr unknown
- 2015-03-26 EA EA201600622A patent/EA032559B1/ru unknown
- 2015-03-26 ES ES19157789T patent/ES2910128T3/es active Active
- 2015-03-26 JP JP2016560419A patent/JP6177456B2/ja active Active
- 2015-03-26 NZ NZ724578A patent/NZ724578A/en not_active IP Right Cessation
- 2015-03-26 CR CR20160456A patent/CR20160456A/es unknown
- 2015-03-26 EP EP15717250.3A patent/EP3126330B1/fr active Active
- 2015-03-26 WO PCT/IB2015/052251 patent/WO2015150995A1/fr not_active Ceased
- 2015-03-26 DK DK15717250.3T patent/DK3126330T3/en active
- 2015-03-26 ME MEP-2019-113A patent/ME03599B/fr unknown
- 2015-03-26 HR HRP20190506TT patent/HRP20190506T1/hr unknown
- 2015-03-26 MX MX2016013052A patent/MX374729B/es active IP Right Grant
- 2015-03-26 CN CN201580029784.3A patent/CN106458912B/zh active Active
- 2015-03-26 CU CU2016000149A patent/CU24406B1/es unknown
- 2015-03-26 HU HUE19157789A patent/HUE057876T2/hu unknown
- 2015-03-26 EP EP19157789.9A patent/EP3536685B1/fr active Active
- 2015-03-26 PL PL19157789T patent/PL3536685T3/pl unknown
- 2015-03-26 MD MDA20160106A patent/MD4779B1/ro not_active IP Right Cessation
- 2015-03-26 BR BR112016023117-1A patent/BR112016023117B1/pt active IP Right Grant
- 2015-03-26 SI SI201531825T patent/SI3536685T1/sl unknown
- 2015-03-26 PT PT191577899T patent/PT3536685T/pt unknown
- 2015-03-26 PL PL15717250T patent/PL3126330T3/pl unknown
- 2015-03-26 GE GEAP201814288A patent/GEAP201814288A/en unknown
- 2015-03-26 RS RS20220257A patent/RS63024B1/sr unknown
- 2015-03-26 CA CA2944475A patent/CA2944475C/fr active Active
- 2015-03-26 GE GEAP201514288A patent/GEP20186887B/en unknown
- 2015-03-26 HU HUE15717250 patent/HUE044180T2/hu unknown
- 2015-03-26 SI SI201530676T patent/SI3126330T1/sl unknown
- 2015-03-26 AP AP2016009514A patent/AP2016009514A0/en unknown
- 2015-03-26 ES ES15717250T patent/ES2718552T3/es active Active
- 2015-03-26 PT PT15717250T patent/PT3126330T/pt unknown
- 2015-03-26 LT LTEP19157789.9T patent/LT3536685T/lt unknown
- 2015-03-26 PE PE2016001905A patent/PE20161251A1/es unknown
- 2015-03-26 LT LTEP15717250.3T patent/LT3126330T/lt unknown
- 2015-03-26 MY MYPI2016703626A patent/MY192521A/en unknown
- 2015-03-26 MA MA39838A patent/MA39838B1/fr unknown
- 2015-03-26 SG SG11201608110WA patent/SG11201608110WA/en unknown
- 2015-03-26 TR TR2019/04658T patent/TR201904658T4/tr unknown
- 2015-03-26 HR HRP20220362TT patent/HRP20220362T1/hr unknown
- 2015-03-26 KR KR1020167030630A patent/KR101901044B1/ko active Active
- 2015-03-26 AU AU2015242291A patent/AU2015242291B2/en active Active
- 2015-03-26 UA UAA201610113A patent/UA121467C2/uk unknown
- 2015-03-26 MA MA52856A patent/MA52856B1/fr unknown
- 2015-03-26 DK DK19157789.9T patent/DK3536685T3/da active
- 2015-03-27 UY UY0001036056A patent/UY36056A/es not_active Application Discontinuation
- 2015-04-01 AR ARP150101019A patent/AR099955A1/es not_active Application Discontinuation
- 2015-04-02 TW TW105117087A patent/TWI580678B/zh active
- 2015-04-02 TW TW106105786A patent/TWI623530B/zh active
- 2015-04-02 TW TW104111016A patent/TWI593683B/zh active
- 2015-04-03 US US14/678,114 patent/US9458168B2/en active Active
2016
- 2016-08-10 US US15/232,892 patent/US9879022B2/en active Active
- 2016-09-22 ZA ZA2016/06550A patent/ZA201606550B/en unknown
- 2016-09-26 EC ECIEPI201676566A patent/ECSP16076566A/es unknown
- 2016-09-29 IL IL248158A patent/IL248158B/en active IP Right Grant
- 2016-09-30 SV SV2016005295A patent/SV2016005295A/es unknown
- 2016-10-03 DO DO2016000271A patent/DOP2016000271A/es unknown
- 2016-10-03 NI NI201600152A patent/NI201600152A/es unknown
- 2016-10-04 PH PH12016501972A patent/PH12016501972A1/en unknown
- 2016-10-04 CL CL2016002524A patent/CL2016002524A1/es unknown
- 2016-10-04 GT GT201600215A patent/GT201600215A/es unknown
2017
- 2017-07-11 JP JP2017135751A patent/JP6492128B2/ja active Active
2018
- 2018-01-05 US US15/862,691 patent/US10329302B2/en active Active
2019
- 2019-04-12 CY CY20191100413T patent/CY1121694T1/el unknown
- 2019-05-14 US US16/411,679 patent/US10793579B2/en active Active
2020
- 2020-08-18 US US16/996,117 patent/US11702424B2/en active Active
2022
- 2022-03-31 CY CY20221100251T patent/CY1125110T1/el unknown
2023
- 2023-06-28 US US18/342,977 patent/US12202836B2/en active Active

Also Published As

Publication number	Publication date
LT3536685T (lt)	2022-04-25
AR099955A1 (es)	2016-08-31
EP3536685B1 (fr)	2022-02-16
SI3536685T1 (sl)	2022-05-31
JP2017206549A (ja)	2017-11-24
US20190270751A1 (en)	2019-09-05
CA2944475A1 (fr)	2015-10-08
US11702424B2 (en)	2023-07-18
SI3126330T1 (sl)	2019-05-31
CR20160456A (es)	2016-12-01
WO2015150995A1 (fr)	2015-10-08
BR112016023117A2 (fr)	2017-08-15
TW201540707A (zh)	2015-11-01
LT3126330T (lt)	2019-04-25
GEAP201814288A (en)	2018-05-10
US20180127432A1 (en)	2018-05-10
GT201600215A (es)	2018-10-19
US10793579B2 (en)	2020-10-06
PT3126330T (pt)	2019-04-29
US10329302B2 (en)	2019-06-25
US20200377511A1 (en)	2020-12-03
TW201630903A (zh)	2016-09-01
HRP20190506T1 (hr)	2019-05-03
JP6492128B2 (ja)	2019-03-27
JP6177456B2 (ja)	2017-08-09
BR112016023117B1 (pt)	2023-02-07
US20230339960A1 (en)	2023-10-26
EA032559B1 (ru)	2019-06-28
JP2017512809A (ja)	2017-05-25
US20150284405A1 (en)	2015-10-08
MX2016013052A (es)	2017-01-09
DOP2016000271A (es)	2017-04-16
MA52856A (fr)	2021-04-21
EA201600622A1 (ru)	2017-02-28
TWI580678B (zh)	2017-05-01
TR201904658T4 (tr)	2019-04-22
PL3536685T3 (pl)	2022-05-16
EP3536685A1 (fr)	2019-09-11
ME03599B (fr)	2020-07-20
ECSP16076566A (es)	2017-03-31
CA2944475C (fr)	2018-07-10
PT3536685T (pt)	2022-03-28
DK3126330T3 (en)	2019-04-23
US9458168B2 (en)	2016-10-04
US9879022B2 (en)	2018-01-30
MD20160106A2 (ro)	2017-03-31
US12202836B2 (en)	2025-01-21
KR101901044B1 (ko)	2018-09-20
MX374729B (es)	2025-03-06
ES2910128T3 (es)	2022-05-11
AP2016009514A0 (en)	2016-10-31
TWI593683B (zh)	2017-08-01
AU2015242291B2 (en)	2018-08-30
NZ724578A (en)	2019-05-31
PE20161251A1 (es)	2016-11-30
CU24406B1 (es)	2019-05-03
AU2015242291A1 (en)	2016-10-13
SG11201608110WA (en)	2016-10-28
CN106458912B (zh)	2020-10-27
PH12016501972B1 (en)	2016-12-19
CU20160149A7 (es)	2017-04-05
US20160347760A1 (en)	2016-12-01
PL3126330T3 (pl)	2019-09-30
DK3536685T3 (da)	2022-03-07
HRP20220362T1 (hr)	2022-05-13
EP3126330B1 (fr)	2019-02-27
PH12016501972A1 (en)	2016-12-19
KR20160135363A (ko)	2016-11-25
CN106458912A (zh)	2017-02-22
EP3126330A1 (fr)	2017-02-08
CY1125110T1 (el)	2024-02-16
TWI623530B (zh)	2018-05-11
MA39838A (fr)	2017-02-08
ZA201606550B (en)	2018-05-30
SV2016005295A (es)	2017-03-28
GEP20186887B (en)	2018-08-27
RS58597B1 (sr)	2019-05-31
CY1121694T1 (el)	2020-07-31
ES2718552T3 (es)	2019-07-02
MD4779B1 (ro)	2021-12-31
UA121467C2 (uk)	2020-06-10
TW201722931A (zh)	2017-07-01
CL2016002524A1 (es)	2017-06-09
HUE057876T2 (hu)	2022-06-28
RS63024B1 (sr)	2022-04-29
HUE044180T2 (hu)	2019-10-28
UY36056A (es)	2015-10-30
MA52856B1 (fr)	2022-03-31
MY192521A (en)	2022-08-25
NI201600152A (es)	2016-11-18
IL248158B (en)	2018-06-28

Publication	Publication Date	Title
MA39838B1 (fr)	2019-05-31	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
IL287331A (en)	2021-12-01	Use of 3-isoxazolidinones compounds as selective herbicides
IL284952A (en)	2021-08-31	Bicyclic heterocyclyl derivatives as irak4 inhibitors
IL285114B1 (en)	2023-04-01	Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
HUE053705T2 (hu)	2021-07-28	Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
MA41551A (fr)	2017-12-26	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA46228A (fr)	2019-07-24	Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
MA52063A (fr)	2021-05-26	Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA40587A (fr)	2017-06-28	Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
EP3250035A4 (fr)	2019-02-27	Composés et leur utilisation en tant qu'inhibiteurs de bace1
MA47576A (fr)	2020-01-01	Composés inhibiteurs d'oga bicyclique
MA42919A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA55194A (fr)	2022-05-04	Composés hétérocycliques en tant qu'immunomodulateurs
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
CL2016002129A1 (es)	2017-06-09	Compuestos de azolina
MA42918A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
EP3119761C0 (fr)	2023-06-07	Agents ciblant les amyloïdes et procédés de leur utilisation
MA45709A (fr)	2019-05-29	Composés diazahétérobicycliques substitués et leur utilisation
EP3328840A4 (fr)	2019-02-20	Composés bicycliques triazolo substitués en tant qu'inhibiteurs de pde2
IL250613B (en)	2020-07-30	Substituted bicyclic compounds
HUE042493T2 (hu)	2019-07-29	Újfajta fuzionált imidazobenzotiazol vegyületek
EP3383388A4 (fr)	2019-06-05	Utilisation d'arylacylsulfonamides en tant qu'antagonistes de blt1
EP3383389A4 (fr)	2019-05-08	Utilisation d'arylacylsulfonamides en tant qu'antagonistes de blt1
EP3497152C0 (fr)	2023-06-07	Composition de polypropylène
EP3363288A4 (fr)	2019-07-03	Composition pour la destruction de microalgues ou de sphaerocarpus